- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Cheap drug protects against contrast-induced nephropathy
As the number of patients undergoing contrast-enhanced CT scans grows, so does the risk of contrast-induced nephropathy. How to protect patients? By asking them to pop an N-acetylcysteine (NAC) pill before the exam.
Principal investigator Dr. Aine M. Kelly and colleagues at the University of Michigan Medical School analyzed data from 41 studies that evaluated several kidney-protecting drugs. They found that patients who took NAC could avoid serious kidney damage caused by iodine-based contrast agents. The drug costs about 25¢ for a 500 mg dose and is available in most pharmacies. The investigators also found NAC outperforms other medicines used for the same purpose. Findings were published in the Feb. 19 issue of the Annals of Internal Medicine.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
